Plain-English translation of NCT07311577 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called disitamab vedotin combined with two other cancer drugs (carboplatin chemotherapy and bevacizumab) as a first-line treatment for women with advanced ovarian cancer. The study is looking at whether this combination is effective and safe for patients whose cancer has certain genetic and protein characteristics. About 43 women will participate in this Phase II study.
Most women with advanced ovarian cancer will eventually need new treatment options because their cancer comes back or becomes resistant to standard therapy. This trial exists to see if this new medication approach can help women with this specific type of ovarian cancer live longer and control their disease better.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication, chemotherapy (carboplatin), and bevacizumab through an IV every 3 weeks during the first treatment phase. If your cancer responds well, you will continue with the new medication alone plus bevacizumab during a maintenance phase, lasting up to 6 months for the new medication and up to 22 cycles (about 15–16 months) for bevacizumab, or until your cancer starts growing again. You will have regular blood tests, imaging scans, and clinic visits to monitor how you're responding to treatment and to watch for side effects.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China